Where is Genmab A/S (GMAB) Headed According to Wall Street?

1 month ago 23

Noor Ul Ain Rehman

Tue, February 10, 2026 astatine 5:41 AM CST 2 min read

Genmab A/S (NASDAQ:GMAB) is 1 of the champion healthcare stocks nether $50 to put in. Genmab A/S (NASDAQ:GMAB) announced connected January 21 that the worldwide nett commercialized income of DARZALEX, including income of the subcutaneous merchandise (daratumumab and hyaluronidase-fihj, sold nether the tradename DARZALEX FASPRO® successful the U.S.), arsenic reported by J&J, came up to $14.351 cardinal successful 2025. Net commercialized income were $8.266 cardinal successful the U.S. and $6.085 cardinal successful the remainder of the world. Management reported that Genmab A/S (NASDAQ:GMAB) receives royalties connected the worldwide nett income of DARZALEX nether the exclusive worldwide licence to J&J for the development, manufacture, and commercialization of daratumumab. This includes some the intravenous and SC products.

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?

In different development, H.C. Wainwright revised the terms people connected Genmab A/S (NASDAQ:GMAB) to $39 from $41 connected January 20, maintaining a Buy standing connected the shares. The steadfast told investors that though EPCORE DLBCL-1 failed its superior endpoint, Epkinly whitethorn inactive summation afloat approval. BofA besides adjusted the terms people connected Genmab A/S (NASDAQ:GMAB) to $38.50 from $34.70 connected January 19, reaffirming a Buy rating. The steadfast stated that the institution antecedently outlined a “catalyst-rich” fiscal 2026, and BofA is “bullish” connected Genmab A/S’s (NASDAQ:GMAB) large catalysts successful 2026 arsenic it believes each could connection a $2 cardinal highest income accidental successful charismatic markets.

Genmab A/S (NASDAQ:GMAB) is an planetary biotechnology institution that develops quality antibody therapeutics for the attraction of crab and different diseases. Its merchandise pipeline includes DARZALEX to dainty definite indications of aggregate myeloma, TEPEZZA for the attraction of thyroid oculus disease, and Arzerra to dainty definite indications of chronic lymphocytic leukemia.

While we admit the imaginable of GMAB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.